Onxeo CEO: Real life does not take place in the clinic
Danish-French biotech group Onxeo is ready to license late-stage candidates. CEO Judith Greciet says one of the biggest challenges in the company is pricing of drugs and points to Gilead’s Sovaldi as a perfect example of the issue.
BY BENJAMIN WERNER CHRISTENSEN
Gilead’s hep C drug Sovaldi is the perfect example of how difficult it can be to price a drug just right, Judith Greciet, CEO of Onxeo, says in an interview with MedWatch. The company hopes to license new candidate drugs, she says, adding that it iwill happen in the longer term.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Here is why Topotarget Chairman stepped back
For abonnenter
Onxeo wins important new patent
For abonnenter
